Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + etoposide + pingyangmycin + prednisone + semustine
- Development stage
- Unknown
- Lead developer
- Stomatological Hospital of Xi'an Jiaotong University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The CEPPS regimen is a multi-agent chemotherapy combination consisting of cisplatin, etoposide, pingyangmycin (bleomycin A5), prednisone, and semustine (Me-CCNU). It was specifically developed and evaluated by the Department of Oral and Maxillofacial Surgery at the Stomatological Hospital of Xi’an Jiaotong University for the treatment of extranodal natural killer/T-cell lymphoma (ENKL), nasal type. The regimen combines DNA-damaging agents (cisplatin, semustine), a topoisomerase II inhibitor (etoposide), a glycopeptide antibiotic that induces DNA strand breaks (pingyangmycin), and a corticosteroid (prednisone). This combination aims to overcome the multi-drug resistance often seen in NK/T-cell lymphomas, which frequently express P-glycoprotein, by utilizing agents with non-overlapping toxicities and distinct mechanisms of action.
- Other names
- cisplatin-etoposide-pingyangmycin-prednisone-semustine regimenMe-CCNU (semustine)Bleomycin A5 (pingyangmycin)
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on cisplatin + etoposide + pingyangmycin + prednisone + semustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + etoposide + pingyangmycin + prednisone + semustine.